新型脂质体在抗肿瘤药物研究中的进展  

Progress of novel liposomes in anti-tumor drug research

作　　者：董雪荣 贾立华 DONG Xuerong;JIA Lihua(Department of Pharmacy,Peking University International Hospital,Beijing 102206,China)

机构地区：[1]北京大学国际医院药剂科,北京102206

出　　处：《临床药物治疗杂志》2025年第3期11-18,共8页Clinical Medication Journal

基　　金：吴阶平医学基金会科研专项资助基金(320.6750.2024-18-57)。

摘　　要：纳米药物递送系统可以通过纳米药物制备技术对药物进行靶向输送,解决药物溶解度低、靶向性差、毒性大等问题。脂质体是目前临床应用最为成功的纳米药物递送系统,功能化脂质体制剂可通过被动靶向和主动靶向策略将药物精准递送至靶部位,减少药物的毒副作用。刺激响应型脂质体可以在肿瘤特殊环境中触发释药,进一步提高治疗效果。然而,脂质体的临床应用仍面临生产工艺复杂、稳定性不足、靶向性有限和成本高昂等挑战,导致其临床应用受限。本文综述了纳米药物递送系统和新型脂质体在抗肿瘤药物研究中的最新进展,总结了上市后和临床研究中的脂质体制剂,并展望了其未来发展方向。The nanomedicine delivery system can target drugs through nanomedicine preparation technology,solving problems such as low drug solubility,poor targeting,and high toxicity.Liposomes are currently the most widely used nanomedicine delivery system in clinical practice.Functionalized liposomes can accurately deliver drugs to target sites through passive and active targeting strategies,reducing drug toxicity and side effects.Triggering responsive liposomes can trigger drug release in the unique tumor environment,further enhancing therapeutic efficacy.However,the clinical application of liposomes still faces challenges such as complex production processes,insufficient stability,limited targeting,and high costs,which limit their clinical application.This article reviews the latest research progress of nanomedicine delivery systems and novel liposomes in the application of anti-tumor drugs,summarizes clinical research and post market liposome formulations,and looks forward to their future development directions.

关 键 词：纳米药物递送系统 新型脂质体 抗肿瘤药物 

分 类 号：R943[医药卫生—药剂学] R979.1[医药卫生—药学]